- Home
- OMGA
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 119.7M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 366.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $10.09 | Next Earning Date: | 05-06-2024 |
| Revenue: | $4,939,000 | Revenue Growth: | 112.70% |
| Revenue Growth (this year): | 33.19% | Revenue Growth (next year): | -80.20% |
Share on Social Networks:
Latest Omega Therapeutics Inc. News
OMGA Breaking Stock News: Dive into OMGA Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Simply Wall St.
13 days ago
Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Zacks
14 days ago
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
14 days ago
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Zacks
25 days ago
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
GlobeNewswire
a month ago
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Zacks
a month ago
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
GlobeNewswire
a month ago